VERAXA Biotech Presents BiTAC Cancer Platforms at BIO International Convention, Highlighting Partnering Opportunities

VERAXA Biotech (NASDAQ: VRXA) is highlighting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, taking place June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.

VERAXA said the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention, scheduled for June 22-25, 2026, in San Diego.

The company’s BiTAC platforms represent a significant advancement in antibody-based therapeutics. BiTAC-ADCs combine bispecific targeting with antibody-drug conjugate technology to deliver cytotoxic agents directly to tumor cells, while BiTAC-TCEs are bispecific T cell engagers designed to recruit the immune system to attack cancer cells. The new proof-of-concept data demonstrate tumor-restricted activation, which could reduce the side effects commonly associated with cancer therapies.

VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond.

The announcement is important because it highlights VERAXA's progress in developing more precise cancer treatments that could improve patient outcomes. The BiTAC platforms address key challenges in oncology, such as off-target toxicity and limited efficacy against solid tumors. By seeking partnerships at the BIO International Convention, VERAXA aims to accelerate the development and commercialization of these technologies, potentially bringing new treatment options to patients faster. The full press release is available at https://ibn.fm/r8zEz, and the latest news and updates relating to VRXA can be found in the company’s newsroom at https://ibn.fm/VRXA.

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include those discussed under "Risk Factors" in the company's filings with the SEC. Undue reliance should not be placed on forward-looking statements, which speak only as of the date hereof.